NEOG vs LNTH vs CBLL Stock Comparison

Neogen, Lantheus Holdings and Ceribell Prices as of Oct 26, 2026 Peers: Industry group
NEOG Neogen Corp
$12.21 -11.3% 1M +97.3% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
LNTH Lantheus Holdings, Inc.
$99.92 +0.2% 1M +78.2% 1Y
Market cap
$6.52B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
8 wins
CBLL Ceribell, Inc.
$27.03 +14.1% 1M +109.7% 1Y
Market cap
$1.03B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

10 decided of 12

Lantheus Holdings leads on 8 of the 12 questions below (Lantheus Holdings 8, Ceribell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNEOGLNTHCBLLLeader
Larger companyMarket capitalisation $2.72B $6.52B $1.03B LNTH
Cheaper on earningsLower P/E, profitable companies only -48.5x 23.7x -15.7x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 38.2x 17.3x — LNTH
Faster revenue growthRevenue growth, trailing twelve months -0.3% +2.3% +31.7% CBLL
More profitableNet margin, trailing twelve months -6.3% 17.7% -64.7% LNTH
Better return on capitalReturn on invested capital -0.2% 12.5% — LNTH
Less leveragedLower net debt / EBITDA 5.4x -0.1x 1.6x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +97.3% +78.2% +109.7% CBLL
Better 5-year returnAnnualised price return, 5 years -21.6%/yr +34.7%/yr — LNTH
Less volatileAnnualised volatility, 1 year 55.7% 32.4% 52.2% LNTH
Higher overall scoreMean of the five percentile scores vs peers 57/100 80/100 38/100 LNTH

Percentile Scorecard

NEOGLNTHCBLL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNEOGLNTHCBLL
Valuation 73 #63 of 228 81 #45 of 228 21 #180 of 228
Growth 49 #114 of 221 63 #83 of 221 21 #175 of 221
Profitability 61 #81 of 208 94 #13 of 208 37 #132 of 208
Financial Health 46 #129 of 239 69 #74 of 239 81 #46 of 239
Shareholder Returns 57 #59 of 137 93 #11 of 137 29 #97 of 137
Overall 57 80 38
  • NEOG ranked among 248 companies in Medical Devices and Diagnostics
  • LNTH ranked among 248 companies in Medical Devices and Diagnostics
  • CBLL ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNEOGLNTHCBLLSPY
1 month -11.3%+0.2%+14.1% -0.8%
3 months +30.7%-7.5%+49.1% +3.5%
6 months +29.2%+18.8%+27.9% +7.0%
Year to date +74.7%+50.1%+23.3% +12.2%
1 year +97.3%+78.2%+109.7% +13.0%
3 years -20.3%+49.5%— +86.3%
3 years, per year -7.3%+14.4%— +23.1%
5 years -70.3%+343.3%— +68.6%
5 years, per year -21.6%+34.7%— +11.0%
10 years -36.4%+1,048.5%— +258.0%
10 years, per year -4.4%+27.7%— +13.6%

Risk

MeasureNEOGLNTHCBLLSPY
Volatility, 1Y 55.7%32.4%52.2% 12.7%
Downside volatility, 1Y 46.5%27.5%49.5% 12.7%
Beta vs S&P 500, 1Y 1.440.591.21 1.00
Return / volatility, 1Y 1.752.422.10 1.02
Max drawdown, 5Y -90.6%-59.5%-63.9% -25.4%
From 52-week high -12.7%-9.9%-2.3% -1.8%
52-week high $13.98$110.94$27.68 $779.14
52-week low $5.41$50.69$10.92 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNEOGLNTHCBLL
P/E now vs peer median -47.5xmedian 30.6x 23.6xmedian 30.6x -15.6xmedian 30.6x
P/S now vs peer median 3.0xmedian 3.0x 4.2xmedian 3.0x 10.1xmedian 3.0x
EV/EBITDA now vs peer median 29.5xmedian 17.5x 16.4xmedian 17.5x -13.5xmedian 17.5x
P/FCF now vs peer median 53.5xmedian 23.3x 16.8xmedian 23.3x -18.9xmedian 23.3x
P/B now vs peer median 1.3xmedian 2.4x 5.0xmedian 2.4x 8.1xmedian 2.4x
PEG now vs peer median 1.69median 0.87 0.22median 0.87 —median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNEOGLNTHCBLL
Revenue $883.99M $1.56B $101.96M
Gross profit $418.98M $936.02M $90.65M
Operating income -$7.38M $302.34M -$69.97M
Net income -$56.10M $275.31M -$66.00M
Free cash flow $49.80M $387.83M -$54.72M
R&D $19.76M $173.09M $22.95M
EPS (diluted) $-0.26 $4.08 $-1.74
Cash & equivalents $172.00M $593.30M $32.66M
Total debt $774.20M $571.05M $19.98M
Shares (diluted) 218.10M 67.52M 38.03M
Enterprise value $2.06B $4.69B $436.22M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNEOGLNTHCBLL
P/E -47.5x 23.6x -15.6x
P/FCF 53.5x 16.8x -18.9x
P/Operating cash flow 31.2x 15.8x -19.1x
P/S 3.0x 4.2x 10.1x
P/B 1.3x 5.0x 8.1x
P/Tangible book 3.4x 10.5x 8.1x
EV/EBITDA 29.5x 16.4x -13.5x
EV/EBIT -443.0x 21.5x -13.2x
EV/Revenue 3.7x 4.2x 9.1x
EV/FCF 65.6x 16.8x -16.9x
EV/Operating cash flow 38.3x 15.7x -17.1x
PEG (3Y EPS CAGR) 1.69 0.22 –

Growth

14 metrics
MetricNEOGLNTHCBLL
Revenue growth (1Y) -0.3% 2.3% 31.7%
Revenue CAGR (3Y) -1.3% 11.4% –
Gross profit growth (1Y) 1.8% -3.4% 33.4%
Gross profit CAGR (3Y) -3.1% 16.3% –
Operating income growth (1Y) 99.3% -30.9% -34.6%
Operating income CAGR (3Y) -29.0% 118.8% –
Net income growth (1Y) 94.6% 1.6% -33.6%
Net income CAGR (3Y) -28.3% 102.1% –
EPS growth (1Y) 94.6% 5.8% -27.5%
EPS CAGR (3Y) -28.0% 105.5% –
Operating cash flow growth (1Y) -1.9% -21.7% -44.3%
Operating cash flow CAGR (3Y) 2.9% 14.5% –
Free cash flow growth (1Y) 1,631% -10.1% -41.8%
Free cash flow CAGR (3Y) 126.1% 103.0% –

Profitability

14 metrics
MetricNEOGLNTHCBLL
Gross margin 47.4% 60.1% 88.9%
EBITDA margin 12.5% 25.4% -67.1%
Operating margin -0.8% 19.4% -68.6%
Pretax margin -7.7% 23.3% -64.7%
Net margin -6.3% 17.7% -64.7%
FCF margin 5.6% 24.9% -53.7%
Operating cash flow margin 9.6% 26.5% -53.0%
Return on equity -2.7% 21.8% -49.0%
Return on assets -1.7% 11.6% -38.3%
Return on invested capital -0.2% 12.5% –
Return on capital employed -0.2% 14.8% -45.1%
Asset turnover 0.3x 0.7x 0.6x
Cash conversion (OCF / net income) -1.5x 1.5x 0.8x
Stock comp / revenue 1.3% 5.0% 16.1%

Financial Health

11 metrics
MetricNEOGLNTHCBLL
Debt / assets 23.4% 23.6% 12.0%
Debt / equity 0.4x 0.4x 0.2x
Net debt / EBITDA 5.4x -0.1x 1.6x
Debt / FCF 15.5x 1.5x -0.4x
Liabilities / assets 36.8% 45.7% 22.9%
Equity / assets 63.2% 54.3% 77.1%
Interest coverage – 15.3x -38.6x
Current ratio 3.9x 3.1x 9.2x
Quick ratio 2.1x 2.8x 8.6x
Cash ratio 1.2x 1.8x 7.5x
Altman Z-score 1.50 5.46 14.35

Shareholder Returns

7 metrics
MetricNEOGLNTHCBLL
Dividend yield – – –
Net buyback yield -0.1% 2.9% -0.6%
Shareholder yield -0.1% 2.9% -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNEOGLNTHCBLL
Forward P/E 38.2xFY2026 17.3xFY2026 –
EPS, next fiscal year $0.32FY2026 $5.76FY2026 $-1.86FY2026
EPS growth, next FY 0.0%FY2026 -5.3%FY2026 –
EPS growth, the year after +31.3% +4.2% –
Revenue, next fiscal year $847.28MFY2026 $1.57BFY2026 $118.32MFY2026
Revenue growth, next FY -2.7%FY2026 +1.8%FY2026 +32.9%FY2026
Revenue growth, the year after -1.5% +12.7% +21.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNEOGLNTHCBLL
Held by institutions 100.0% 100.0% 79.9%
Institutions holding 315 465 124
Change in shares held, QoQ +1.6% +3.4% +2.2%
Institutions buying 151 248 74
Institutions selling 106 142 36
Buyers to sellers 1.42 1.75 2.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NEOGLNTHCBLL
NEOG 1.00 0.08 0.25
LNTH 0.08 1.00 0.21
CBLL 0.25 0.21 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NEOG, LNTH and CBLL?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Neogen (NEOG) $2.72B, Lantheus Holdings (LNTH) $6.52B, Ceribell (CBLL) $1.03B.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Neogen (NEOG) -0.3%, Lantheus Holdings (LNTH) +2.3%, Ceribell (CBLL) +31.7%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Neogen (NEOG) -6.3%, Lantheus Holdings (LNTH) 17.7%, Ceribell (CBLL) -64.7%). On return on invested capital, Lantheus Holdings (LNTH) leads (Neogen (NEOG) -0.2%, Lantheus Holdings (LNTH) 12.5%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Neogen (NEOG) +97.3%, Lantheus Holdings (LNTH) +78.2%, Ceribell (CBLL) +109.7%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Neogen (NEOG) -21.6%/yr, Lantheus Holdings (LNTH) +34.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Neogen (NEOG) 55.7%, Lantheus Holdings (LNTH) 32.4%, Ceribell (CBLL) 52.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NEOG, LNTH and CBLL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.